Biotech ETF $XBI Drops 2% Amid Buyouts, Rate Cuts, and Weak Sentiment Despite Pharma’s Low Valuations

The biotechnology sector, represented by the $XBI ETF, is experiencing a notable downturn, with the market declining by approximately 2%. Investor sentiment towards biotech remains subdued compared to the broader market, which has shown signs of recovery. Concerns include management issues and regulatory appointments that have deterred investment. Despite this, some market participants find the pharmaceutical industry attractive due to its low valuations, high uncertainty, and defensive positioning amid a market environment where most sectors are pursuing growth strategies. The sector has seen buyouts and interest in rate cuts, but overall sentiment remains weak.